CBLB and leukemia: Should human leukemia patients with Cbl mutations exhibit impaired HSC quiescence and self-renewal, as shown with Cbl/Cbl-b DKO mice here, targeting of their actively cycling leukemogenic HSCs could provide a novel “exhaustion” therapy for these patients.